Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 10/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805821 | 1.00 | VCAM1 (0.54) | VCAM1MAPTLMNAMEN1GAA | |
| SCHEMBL2726273 | 0.98 | VCAM1 (0.53) | VCAM1MAPTLMNAMEN1GAA | |
| SCHEMBL2726271 | 0.82 | VCAM1 (0.50) | VCAM1MAPTTDP1MAPK1ALDH1A1 | |
| SCHEMBL11227558 | 0.79 | ALDH1A1 (0.53) | MAPTLMNAMEN1GAAKMT2A | |
| SCHEMBL28990036 | 0.79 | TDP1 (0.56) | MAPTLMNAMEN1GAAHTT | |
| SCHEMBL6519433 | 0.79 | CASP6 (0.37) | VCAM1LMNAMAPK1ALDH1A1HPGD | |
| SCHEMBL19188309 | 0.78 | ALDH1A1 (0.47) | VCAM1MAPTLMNATDP1MAPK1 | |
| SCHEMBL6513974 | 0.77 | CASP6 (0.36) | VCAM1LMNAMAPK1ALDH1A1HPGD | |
| SCHEMBL6513978 | 0.77 | CASP6 (0.36) | VCAM1LMNAMAPK1ALDH1A1HPGD | |
| SCHEMBL6519958 | 0.77 | CASP6 (0.36) | VCAM1LMNAMAPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171849-A1 | Deprotecting peptide from allyl-type protecting groups by palladium catalysis in presence of allyl acceptor; lactamization; solid phase synthesis | LONZA AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1794180-B1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1794180-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032457-A9 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006032457-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171849-A1 | Deprotecting peptide from allyl-type protecting groups by palladium catalysis in presence of allyl acceptor; lactamization; solid phase synthesis | PEPD, VIP, DNPEP | VCAM1 2956/4885MAPT 4539/4885LMNA 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.